Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Adjuvant capecitabine after surgery for CK19-related hepatocellular carcinoma
ChiCTR2000041418Phase 4Recruiting
- Sponsor
- Cancer Hospital of Guangxi Medical University
- Start
- Aug 2020
- Modality
- Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules, Irreversible Covalent Inhibitors → Covalent Small Molecules → Small Molecules, DNA Intercalators/Alkylators → Nucleic Acid-Directed Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 4, randomised, open-label trial of capecitabine in hepatocellular carcinoma (HCC) (4 arms), sponsored by Cancer Hospital of Guangxi Medical University. Primary endpoints: Time to recurrence and Disease-free survival. Started Aug 2020; status: recruiting.
02
Drugs
capecitabine
03
Conditions
hepatocellular carcinoma (HCC)
Beyond the preview
Go deeper on ChiCTR2000041418.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2000041418.